Calcineurin inhibitors and rapamycin: cancer protection or promotion?
about
Topical treatments for scalp psoriasisTopical tacrolimus for atopic dermatitisCyclophilin D interacts with Bcl2 and exerts an anti-apoptotic effectIncidence, risk factors and outcomes of de novo malignancies post liver transplantationMurine atopic dermatitis responds to peroxisome proliferator-activated receptors alpha and beta/delta (but not gamma) and liver X receptor activators.CypA, a gene downstream of HIF-1α, promotes the development of PDACHepatocellular carcinoma following renal transplantation.Systematic review of published trials: long-term safety of topical corticosteroids and topical calcineurin inhibitors in pediatric patients with atopic dermatitis.The use of topical calcineurin inhibitors in lupus erythematosus: an overview.Chromosomal aberrations in UVB-induced tumors of immunosuppressed mice.Synergistic anti-cancer effects of immunotoxin and cyclosporin in vitro and in vivo.Angiogenesis drives psoriasis pathogenesis.Therapeutic approaches to epileptogenesis--hope on the horizon.Critical review of preclinical approaches to evaluate the potential of immunosuppressive drugs to influence human neoplasia.Life-long diseases need life-long treatment: long-term safety of ciclosporin in canine atopic dermatitis.Photocarcinogenicity of selected topically applied dermatological drugs: calcineurin inhibitors, corticosteroids, and vitamin D analogs.Post-transplantation malignancies: here today, gone tomorrow?VEGF involvement in psoriasis.Development of a squamous cell carcinoma mouse model for immunotoxicity testing.FKBP51 protects 661w cell culture from staurosporine-induced apoptosis.Topical herbal extract (Huangdang mixture) exhibits both preventive and therapeutic effects in murine acute irritant contact dermatitis.Astragaloside IV Ameliorates Airway Inflammation in an Established Murine Model of Asthma by Inhibiting the mTORC1 Signaling Pathway.Hippocampal CA3 calcineurin activity participates in depressive-like behavior in rats.Pimecrolimus 1% cream for oral erosive lichen planus: a 6-week randomized, double-blind, vehicle-controlled study with a 6-week open-label extension to assess efficacy and safety.
P2860
Q24186104-46029447-D340-44B1-A5F6-81524DEB898AQ24186624-1FD5E6B6-2574-4BC8-856A-B6FED74A4F73Q24312297-7E3E4300-4DED-4338-9D7C-F0585A3F545CQ26748580-5FC5BC4F-5AB6-4C28-BFE5-F32BA1B4E52AQ30494234-D4861C51-C27E-42C8-A25F-4DC2B9C5C914Q35129112-E43EE524-B3FD-4979-AAEB-95EF2B636D79Q35715435-7F313E50-FAA0-47A0-8567-32CE33800372Q36042131-95865E4F-B9B4-487F-8EEF-F69FB03E3999Q37001577-5BC3B3F5-7AE9-4AF8-8219-94BC76E260F1Q37337088-37D00335-BD93-4A60-990F-6476E34C1B01Q37401525-32D5608B-683F-4E63-88A0-2F61CE3F30A3Q37534974-B48CC012-49E1-4A4C-8710-D0B6E4E10E64Q37771378-0AC75E4A-ED71-46D7-864A-6EF6BE106879Q37795414-87033673-4DBD-4F59-ADCB-013A3073E276Q38200540-20B3F203-4982-447C-A002-CA3760094BECQ38266892-479D1DB4-C067-4479-9C05-3154AE5A066DQ38611709-7083BA0D-9C0E-4F23-8342-EA1FAB68EDFFQ38648336-CC1407E3-08EE-4B1D-A305-6977403B8F60Q38871984-7094B607-B5C4-4312-B291-AF4949E16C75Q39535549-433F7B4F-C930-4662-90DD-F0FEE74233B5Q46069466-8D895F92-7CE3-4649-9C69-4B89E10F5CFBQ47093766-EFBE7C1C-6FE4-4E1A-BD29-0F7CF7781AF0Q48882481-93E7E286-2399-4915-B45D-A6AF1CCD2B83Q51738129-587970A6-3FC7-468C-8E8C-780E50167772
P2860
Calcineurin inhibitors and rapamycin: cancer protection or promotion?
description
2007 nî lūn-bûn
@nan
2007 թուականի Մայիսին հրատարակուած գիտական յօդուած
@hyw
2007 թվականի մայիսին հրատարակված գիտական հոդված
@hy
2007年の論文
@ja
2007年論文
@yue
2007年論文
@zh-hant
2007年論文
@zh-hk
2007年論文
@zh-mo
2007年論文
@zh-tw
2007年论文
@wuu
name
Calcineurin inhibitors and rapamycin: cancer protection or promotion?
@ast
Calcineurin inhibitors and rapamycin: cancer protection or promotion?
@en
Calcineurin inhibitors and rapamycin: cancer protection or promotion?
@nl
type
label
Calcineurin inhibitors and rapamycin: cancer protection or promotion?
@ast
Calcineurin inhibitors and rapamycin: cancer protection or promotion?
@en
Calcineurin inhibitors and rapamycin: cancer protection or promotion?
@nl
prefLabel
Calcineurin inhibitors and rapamycin: cancer protection or promotion?
@ast
Calcineurin inhibitors and rapamycin: cancer protection or promotion?
@en
Calcineurin inhibitors and rapamycin: cancer protection or promotion?
@nl
P2093
P2860
P1476
Calcineurin inhibitors and rapamycin: cancer protection or promotion?
@en
P2093
Maren Weischer
Mark Berneburg
Martin Röcken
P2860
P304
P356
10.1111/J.1600-0625.2007.00555.X
P577
2007-05-01T00:00:00Z